| 4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow |
Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025. |
zacks.com |
2024-12-24 14:51:19 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome |
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced new data from an analysis of nine patients treated with an initial 2 or 3 doses of 70mg, followed by 45mg maintenance dosing in the Phase 1/2a and open-label extension (OLE) studies of zorevunersen. Substantial and durable reductions in convulsive seizure frequency were observed in these. |
businesswire.com |
2024-12-06 14:00:00 |
Czytaj oryginał (ang.) |
| STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug |
The FDA bestows a Breakthrough Therapy designation to Stoke Therapeutics' zorevunersen for the treatment of Dravet syndrome. Stock rises. |
zacks.com |
2024-12-05 13:15:27 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting |
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced several presentations at the American Epilepsy Society (AES) 2024 Annual Meeting, taking place December 6 – 10, in Los Angeles, California. In addition, the Company will host a virtual event with discussions led by leading clinicians and patient advocates for investors and research analys. |
businesswire.com |
2024-12-02 10:00:00 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now |
Stoke Therapeutics (STOK) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
zacks.com |
2024-11-20 12:55:29 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade |
The average of price targets set by Wall Street analysts indicates a potential upside of 66.8% in Stoke Therapeutics (STOK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-11-08 12:55:21 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates |
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.55 per share a year ago. |
zacks.com |
2024-11-05 11:16:11 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release |
Stoke Therapeutics (STOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-29 13:06:14 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome |
STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming for topline data by mid-2026. |
seekingalpha.com |
2024-09-07 08:03:26 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics to Present at Upcoming Investor Conferences in September |
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment Conference Date: Tuesday, September 10, 2024 Time: 12:00 p.m. ET 2024 Cantor Fitzgerald Global Healthcare Conference Date: Tuesday, September 17, 2024 Time: 11:30 a.m. |
businesswire.com |
2024-09-03 12:00:00 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates |
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.69 per share a year ago. |
zacks.com |
2024-08-07 13:26:05 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that, effective on July 15, 2024, the company granted stock options to purchase an aggregate of 122,900 shares of common stock to three new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have a. |
businesswire.com |
2024-07-16 20:30:00 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on June 17, 2024, the company granted stock options to purchase an aggregate of 10,400 shares of common stock to one new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options. |
businesswire.com |
2024-06-18 20:30:00 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome |
Stoke Therapeutics' TANGO platform enhances RNA output to compensate for gene mutations causing severe genetic diseases. STOK primarily focuses on developing treatments for Dravet syndrome and autosomal dominant optic atrophy (ADOA). STK-001, a Phase 1/2 candidate for Dravet syndrome, shows promising clinical results with seizure reduction and cognitive improvements. |
seekingalpha.com |
2024-06-14 16:10:53 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics to Present at Upcoming Investor Conferences in June |
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldman Sachs 45th Annual Global Healthcare Conference Date: Monday, June 10, 2024 Time: 4:00 p.m. ET TD Cowen Genetic Medicines & RNA Summit Date: Thursday, June 20, 2024 Time: 1. |
businesswire.com |
2024-06-03 20:30:00 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on May 15, 2024, the company granted stock options of common stock to Thomas Leggett, the Company's newly-appointed Chief Financial Officer, and four other new employees as a material inducement to their employment in accordance with Nasdaq Lis. |
businesswire.com |
2024-05-17 20:30:00 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates |
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.53 per share a year ago. |
zacks.com |
2024-05-06 13:06:06 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates |
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company's proprietary antisense oligonucleotide (ASO) which is in development by Stoke as the first potential medicine to address the genetic c. |
businesswire.com |
2024-05-06 11:00:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline |
Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-04-25 15:07:15 |
Czytaj oryginał (ang.) |
| Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer |
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership. |
businesswire.com |
2024-04-17 12:00:00 |
Czytaj oryginał (ang.) |